Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars

Enliven Therapeutics Inc. (NASDAQ:ELVN) stock is trading higher on Thursday, with a session volume of 6.61 million compared to the average volume of 631.52 thousand as per data from Benzinga Pro.The clinical-stage biopharmaceutical company shared encouraging initial data from the ongoing Phase 1b ENABLE trial of ELVN-001 in patients with chronic myeloid leukemia (CML) that is relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs).DataAs of the cutoff date of December 22, 2025, 60 ...